licensing

News

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou

News

MSD adds bispecific cancer antibody via $1.3bn Curon deal

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies.

News

Ipsen builds again, licensing Day One glioma drug

Ipsen has signed yet another portfolio-expanding deal – its fifth of the year so far – claiming rights outside the US to a drug for common brain cancer glioma from Day One Biopharmaceutical

News

Ipsen forges another ADC alliance, this time with Foreseen

Ipsen’s big partnering push to expand its pipeline shows no signs of abating, with the latest deal a $1 billion wager on an antibody-drug conjugate (ADC) for cancer developed by Foreseen Bi

News

GSK goes all-in on CureVac’s mRNA vaccines

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and

News

AbbVie licenses FutureGen IBD drug in $1.7bn deal

The high value attached by pharma companies to inflammation and immunology (I&I) programmes is on display once again, as AbbVie agrees a deal worth up to $1.7 billion for an inflammator

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

MSD adds bispecific cancer antibody via $1.3bn Curon deal

Ipsen builds again, licensing Day One glioma drug

Ipsen forges another ADC alliance, this time with Foreseen

GSK goes all-in on CureVac’s mRNA vaccines

AbbVie licenses FutureGen IBD drug in $1.7bn deal

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

licensing

Editor's Picks